These innovative molecules represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://kianaajkc045073.blogpayz.com/39366683/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide